Logo image of KME.MI

KME GROUP SPA (KME.MI) Stock Fundamental Analysis

Europe - Euronext Milan - BIT:KME - IT0004552359 - Common Stock

0.906 EUR
+0.03 (+2.95%)
Last: 1/5/2026, 7:00:00 PM
Fundamental Rating

2

Overall KME gets a fundamental rating of 2 out of 10. We evaluated KME against 42 industry peers in the Metals & Mining industry. KME has a bad profitability rating. Also its financial health evaluation is rather negative. KME does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year KME has reported negative net income.
  • KME had a positive operating cash flow in the past year.
  • In multiple years KME reported negative net income over the last 5 years.
  • KME had a positive operating cash flow in 4 of the past 5 years.
KME.MI Yearly Net Income VS EBIT VS OCF VS FCFKME.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

1.2 Ratios

  • KME's Return On Assets of -3.14% is on the low side compared to the rest of the industry. KME is outperformed by 78.57% of its industry peers.
  • With a Return On Equity value of -34.02%, KME is not doing good in the industry: 88.10% of the companies in the same industry are doing better.
  • The Return On Invested Capital of KME (1.20%) is worse than 66.67% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for KME is significantly below the industry average of 7.48%.
Industry RankSector Rank
ROA -3.14%
ROE -34.02%
ROIC 1.2%
ROA(3y)-1.25%
ROA(5y)1.2%
ROE(3y)-12.27%
ROE(5y)-4.95%
ROIC(3y)1.89%
ROIC(5y)N/A
KME.MI Yearly ROA, ROE, ROICKME.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

  • The Operating Margin of KME (0.96%) is worse than 71.43% of its industry peers.
  • In the last couple of years the Operating Margin of KME has declined.
  • With a Gross Margin value of 27.92%, KME perfoms like the industry average, outperforming 52.38% of the companies in the same industry.
Industry RankSector Rank
OM 0.96%
PM (TTM) N/A
GM 27.92%
OM growth 3YN/A
OM growth 5Y-39.92%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KME.MI Yearly Profit, Operating, Gross MarginsKME.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so KME is destroying value.
  • KME has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for KME has been reduced compared to 5 years ago.
  • KME has a worse debt/assets ratio than last year.
KME.MI Yearly Shares OutstandingKME.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
KME.MI Yearly Total Debt VS Total AssetsKME.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • Based on the Altman-Z score of 0.83, we must say that KME is in the distress zone and has some risk of bankruptcy.
  • KME has a Altman-Z score of 0.83. This is in the lower half of the industry: KME underperforms 76.19% of its industry peers.
  • The Debt to FCF ratio of KME is 15.00, which is on the high side as it means it would take KME, 15.00 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of KME (15.00) is comparable to the rest of the industry.
  • KME has a Debt/Equity ratio of 3.00. This is a high value indicating a heavy dependency on external financing.
  • KME's Debt to Equity ratio of 3.00 is on the low side compared to the rest of the industry. KME is outperformed by 92.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 3
Debt/FCF 15
Altman-Z 0.83
ROIC/WACC0.12
WACC10.15%
KME.MI Yearly LT Debt VS Equity VS FCFKME.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

  • KME has a Current Ratio of 0.77. This is a bad value and indicates that KME is not financially healthy enough and could expect problems in meeting its short term obligations.
  • KME has a worse Current ratio (0.77) than 92.86% of its industry peers.
  • KME has a Quick Ratio of 0.77. This is a bad value and indicates that KME is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.32, KME is not doing good in the industry: 95.24% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.32
KME.MI Yearly Current Assets VS Current LiabilitesKME.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

3

3. Growth

3.1 Past

  • KME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.24%, which is quite impressive.
  • Looking at the last year, KME shows a quite strong growth in Revenue. The Revenue has grown by 12.62% in the last year.
  • The Revenue has been growing by 163.60% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)72.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.55%
Revenue 1Y (TTM)12.62%
Revenue growth 3Y1061.12%
Revenue growth 5Y163.6%
Sales Q2Q%28.64%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KME.MI Yearly Revenue VS EstimatesKME.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KME. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KME.MI Price Earnings VS Forward Price EarningsKME.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of KME is on the same level as its industry peers.
  • Based on the Price/Free Cash Flow ratio, KME is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.59
EV/EBITDA 12.55
KME.MI Per share dataKME.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • KME does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

KME GROUP SPA

BIT:KME (1/5/2026, 7:00:00 PM)

0.906

+0.03 (+2.95%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap257.70M
Revenue(TTM)1.79B
Net Income(TTM)-64.93M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)-63.27%
DP-0.05%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.14
P/FCF 5.59
P/OCF 2.71
P/B 1.35
P/tB N/A
EV/EBITDA 12.55
EPS(TTM)-0.27
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.16
FCFY17.89%
OCF(TTM)0.33
OCFY36.89%
SpS6.3
BVpS0.67
TBVpS-0.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -3.14%
ROE -34.02%
ROCE 1.61%
ROIC 1.2%
ROICexc 1.35%
ROICexgc 2.56%
OM 0.96%
PM (TTM) N/A
GM 27.92%
FCFM 2.57%
ROA(3y)-1.25%
ROA(5y)1.2%
ROE(3y)-12.27%
ROE(5y)-4.95%
ROIC(3y)1.89%
ROIC(5y)N/A
ROICexc(3y)2.23%
ROICexc(5y)N/A
ROICexgc(3y)4.95%
ROICexgc(5y)N/A
ROCE(3y)2.52%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y79.58%
ROICexc growth 3YN/A
ROICexc growth 5Y46.15%
OM growth 3YN/A
OM growth 5Y-39.92%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 3
Debt/FCF 15
Debt/EBITDA 8.7
Cap/Depr 100.74%
Cap/Sales 2.73%
Interest Coverage 0.3
Cash Conversion 144.61%
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.32
Altman-Z 0.83
F-Score5
WACC10.15%
ROIC/WACC0.12
Cap/Depr(3y)57.3%
Cap/Depr(5y)69.14%
Cap/Sales(3y)1.76%
Cap/Sales(5y)10.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.55%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.62%
Revenue growth 3Y1061.12%
Revenue growth 5Y163.6%
Sales Q2Q%28.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y195.37%
EBIT growth 3YN/A
EBIT growth 5Y58.36%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-62.16%
FCF growth 3Y16.77%
FCF growth 5YN/A
OCF growth 1Y-34.19%
OCF growth 3Y29.71%
OCF growth 5YN/A

KME GROUP SPA / KME.MI FAQ

What is the fundamental rating for KME stock?

ChartMill assigns a fundamental rating of 2 / 10 to KME.MI.


Can you provide the valuation status for KME GROUP SPA?

ChartMill assigns a valuation rating of 2 / 10 to KME GROUP SPA (KME.MI). This can be considered as Overvalued.


Can you provide the profitability details for KME GROUP SPA?

KME GROUP SPA (KME.MI) has a profitability rating of 1 / 10.


What is the financial health of KME GROUP SPA (KME.MI) stock?

The financial health rating of KME GROUP SPA (KME.MI) is 1 / 10.


How sustainable is the dividend of KME GROUP SPA (KME.MI) stock?

The dividend rating of KME GROUP SPA (KME.MI) is 0 / 10 and the dividend payout ratio is -0.05%.